The low phenylalanine diet used for the treatment of phenylketonuria requires a protein substitute lowv in phenylalanine. The preparations available are either hydrolysates of natural proteins from which most of the phenylalanine has been removed (Minafen, Cow & Gate; Cymogran, Allen & Hanbury; Albumaid XP, Scientific Hospital Supplies; Lofenalac, Bristol Laboratories (UK) ) or mixtures of pure L-amino acids excluding phenylalanine (Aminogran, Allen & Hanbury; PKU Aid, Scientific Hospital Supplies).
A previous study in children over 20 months of age (Bentovim et al., 1970) showed that Aminogran had advantages over Cymogran. The small bulk and more acceptable taste and smell of the aminoReceived 20 February 1975. acid preparation resulted in a more 'normal' eating pattern. This paper describes the use of Aminogran in a group of infants from the time of diagnosis in the neonatal period, and compares their progress with that of a group treated with protein hydrolysates.
Patients and methods Fifteen consecutive neonates diagnosed as suffering from phenylketonuria as a result of routine Guthrie screening (12 cases) or because of an older affected sib (3 cases) were admitted to hospital to confirm the diagnosis and to start treatment. Initially they were all thought to have classical phenylketonuria (blood phenylalanine level >30 mg/100 ml and phenylpyruvic acid present in urine), but subsequently two were found to have a higher tolerance of natural protein than is usually found in the classical condition. 864
The infants were divided into three groups (Table I) . The first five (group 1) were initially treated with Minafen which was gradually replaced by Aminogran between 3 and 10 months. The next five (group 2) were treated with Aminogran throughout. The last five (group 3) were initially treated with Minafen which was gradually replaced by Cymogran between 3 and 10 months. Treatment was started between 7 and 29 days of age. Over the first year of treatment phenylalanine levels were measured at least fortnightly and the necessary dietary changes were communicated to the mothers within 48 hours of the blood reaching the hospital. The intake of natural protein was adjusted to maintain blood phenylalanine levels between 3 and 8 mg/100 ml. Phenylalanine levels were plotted against age for each patient and the duration of levels above 10 mg/100 ml and below 2 mg/100 ml was calculated from the graph. This procedure, which has been described in a previous study (Smith, Lobascher, and Wolff, 1973) Control of blood phenylalanine levels. Phenylalanine levels below 2 mg/100 ml were rare except in one patient (described later) in whom food intake was erratic. Phenylalanine levels above 10 mg/100 ml were more frequent, usually in association with febrile illnesses or feeding difficulties. Comparisons of the grouped means of the duration of phenylalanine levels over 10 mg/100 ml (see 'Patients and methods') for the first year of dietary treatment (0 *21 ±0 -1 years for group 1; 0-31±0-17 years for group 2; and 0-24±0 14 years for group 3) using a Student's et' test showed no significant difference between the groups.
Investigations. In all patients the results of the following investigations were normal compared with standards in routine use: haemoglobin, red cell appearances, white blood count, platelet count, prothrombin time, sodium, potassium, urea, chloride, bicarbonate, total proteins, albumin, and wrist x-ray examination.
Results differing from normal were obtained for the following: calcium, magnesium, alkaline phosphatase, and plasma amino acids. It must be noted, however, that specimens were not obtained after a long fast whereas the normal data used for comparison for calcium, magnesium, and amino acids were derived from specimens obtained in the fasting state.
Amino acids. Certain amino acids could not be accurately quantified. Taurine was not retained on the sample cartridge. Tryptophan and hydroxyproline appeared as low peaks but could not be estimated precisely. Cystine, asparagine, and glutamine began to disappear if there was delay in handling the specimen. Asparagine and glutamine are converted to aspartic and glutamic acids, which may therefore show corresponding increases. group. The values for asparagine and glutamine were significantly lower, which could be accounted for by loss from the specimen, and citrulline was also reduced. There was no significant difference in amino acid levels between the patients of group 2 (Aminogran) and group I (Minafen/Aminogran), mean values being almost identical for the two groups throughout the first year of treatment.
Calcium. Plasma calcium levels (mean 10 * O mg/100 ml, range 9-6-106 mg/100 ml) before the start of diet were within or just above the normal range (8 *5-10 *5 mg/100 ml) except for one patient, whose level of 7 8 mg/100 ml on the eighth day rose spontaneously to normal over the next 2 weeks. Once dietary treatment had been started levels in all three groups tended to be at the upper limit of normal or above it, ranging from 9 4 to 11 1 mg/100 ml (mean for group 1, 10 .2 mg/100 ml; for group 2, 10 3 mg/100 ml; for group 3, 10 6 mg/100 ml). Over one-quarter of all results (irrespective of the group) exceeded the upper limit of the normal range (10.5 mg/100 ml) and only four results fell below the normal mean of 9*7 mg/100 ml. Fasting specimens obtained in patients with a level above 10-6 mg showed persistently raised levels in 5 patients (two in group 1, one in group 2, and two in group 3).
Magnesium. Plasma levels before the start of the diet were within the normal range (1 *7-2 2 mg/100 ml). On the three dietary regimens they tended to be at the upper limit of the normal range or above it (1 9-2-5 mg/100 ml) (mean for group 1, 2A1 mg/100 ml; for group 2, 2 3 mg/100 ml; for group 3, 2-2 mg/100 ml). In the absence of a control group of normal infants the statistical significance of the departure from normal of calcium and magnesium levels could not be tested. Diet problems. Feeding difficulties occurred in 6 patients during the first year (3 in group 1, 1 in group 2, and 2 in group 3). These problems seemed to result from a disturbed mother/infant relationship rather than directly from the diet itself. The 2 patients who developed the most persistent eating difficulties belonged to families where serious emotional distubrance was obvious from the beginning and where 'mothering' was deficient. In one, a boy fostered from 4 months of age, the diet was changed at 14 months from Cymogran to Aminogran without improvement in the eating problems. When he was 21 months old his care was taken over by a new foster mother and the feeding problems promptly disappeared.
The other case illustrates the value of Aminogran in the management of the feeding problems which commonly occur during the treatment of phenylketonuria.
He was the second child of young parents, the mother being of above-average intelligence. There were serious family conflicts and the older, unaffected sib also had feeding problems. After discharge from hospital the mother reported that the baby was restless, particularly at feeding times, and regurgitated Aminogran, milk supplements, and vitamins. She complained bitterly about the diet and it was difficult to obtain clear information about the infant's food intake. Blood phenylalanine levels fluctuated widely and the patient was seen often by the family doctor for minor illnesses. Despite these difficulties the patient gained weight satisfactorily up to 6 months of age, when weight gain slowed down and eczematous patches appeared on face, trunk, limbs, and buttocks. The mother became increasingly agitated and irrationally 'disciplinarian' with her son. At 9 months the patient was taken to the local hospital on two occasions because of minor injuries. When 16 months old he was admitted to hospital because of failure to gain weight, recurrent skin rashes, and alternating hyper-and hypophenylalaninaemia.
The mother refused psychiatric support but benefited from the opportunities for sympathetic discussion of her many problems and from practical help with treatment. Aminogran was given before meals as medicine in a thick paste consisting of about 3-4 teaspoonfuls per meal while the patient was held on the mother's lap, and this was followed by a drink of fruit juice. The mother was encouraged to give praise when the Aminogran had been taken and to avoid punish- Aminogran supplies only a small part of the total calorie requirements which must therefore be made up with carbohydrate and fat in early infancy and later on with fruit, vegetables, special bread, biscuits, pasta, and other low-protein foods. Such a diet results in a more normal and varied feeding pattern than can be achieved with Cymogran, which has a substantial carbohydrate and fat content so that there is little scope for additional foods.
Another difference between the three dietary regimens concerned bowel function. Aminogran tended to lead to constipation, which was easily corrected by the addition of brown sugar to the feeds. Minafen and Cymogran led to bulky, loose and frequent stools with excoriation of the buttocks in some children and difficulty with toilet training in the toddlers. Loose stools disappeared when Minafen and Cymogran were replaced by Aminogran.
Discussion
This study shows that treating infants with phenylketonuria with a pure amino-acid preparation (Aminogran) as a protein substitute allows for normal growth and development and satisfactory control of blood phenylalanine levels. With the exception of one patient, who had serious feeding difficulties, no clinical, chemical, or haematological evidence ofnutritional deficiency was found withany of the three dietary regimens. During the period of bottle-feeding the prescription and preparation of a diet based on Aminogran is more complicated than that of a diet based on Minafen or Cymogran. Once solid food and the cup replace the bottle Aminogran has advantages because of its small bulk, low calorie content, less unpleasant taste, and lack of smell. Infants receiving Aminogran can be weaned from the bottle earlier and given a more 'normal' toddler diet than is the case with Cymogran. From experience gained in this study we recommend the Minafen/Aminogran regimen as used for group 1. Patients treated with Aminogran are dependent on low-protein foods for most of their calorie requirements, and careful dietetic advice needs to be given to ensure an adequate calorie intake. The management of feeding difficulties was easier with Aminogran than with Minafen or Cymogran.
The high plasma amino-acid levels observed are not unexpected, because it has been shown (Palmer et al., 1973 ) that 3 to 4 hours after a protein meal plasma amino acids reach a peak level oftwo to three times the fasting level. In our study blood was obtained at a similar interval after the administration of protein substitute and comparable plasma amino-acid values were obtained. No difference was observed in amino-acid levels between patients on Aminogran and those on Minafen. Thus the presence of D-amino acids in Minafen did not affect the plasma amino-acid pattern. Snyderman et al. (1968) showed that in children receiving amino-acid-based diets fasting plasma amino-acid levels remain normal even with very high intakes (equivalent to 9 g protein/kg).
There is no obvious explanation for the raised calcium and magnesium levels. Blood specimens were obtained by femoral or jugular puncture by one of us (IS), and the high levels are unlikely to be due to venous stasis. Plasma protein levels were normal. The highest calcium levels occurred during the first 3 months of treatment in children on Aminogran and at the end of the first year in those on Cymogran, which coincided with the maximal intake of calcium and magnesium per kilogram of body weight. This was not, however, in excess of that received by artificially-fed infants in the first year of life. A supplement of vitamin D (400 IU/day) was given as Ketovite liquid (Paines and Byrnes). Studies of the mineral balance in patients on synthetic diets (Alexander, Clayton, and Delves, 1974) have shown that infants on Aminogran are in calcium and magnesium balance comparable with that of normal breast-fed babies. Oral tryptophan loading has been reported to lead to hypercalcaemia (Drummond, et al., 1964) (Clayton et al., 1965) 
